LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Eli Lilly & Co. and Novo Nordisk A/S are competing for drug contracts in the aftermath of drug price scrutiny. Novo has managed to secure a contract with CVS, beating out its competitor. Other news is ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...

Emmy Award-winning actor Eric Stonestreet, known for his portrayal of Cameron Tucker on ABC’s hit sitcom Modern Family, has revealed his private health journey with type 2 diabetes and how medication ...